obeziana wrote:Хотите иметь 10% шанс активизированного заболевания, обманывайте тетю доктора и изворачивайтесь от полного обследования и лечения латентного ТБ.
А риск печеночных осложнений от антиТБ препаратов 0.4%.
Смотрите какие odds вас устраивают
С Вашего позволения подкорректирую цифры гепатотоксичности изониазида:
Isoniazid has been shown to cause chronic hepatitis with or
without cirrhosis, usually with acinar necrosis and inflammation.
However the histologic appearance is indistinguishable
from viral or auto-immune hepatitides. Isoniazid causes hepatotoxicity
in <10% of subjects exposed to the drug...
Risk factors for isoniazid toxicity include Hepatitis B, Hepatitis
C, HIV, alcohol abuse, age, female, slowacetylator phenotype,
concurrent use of rifampicin or pyrazinamide. With
isoniazid, latency may be shortened when used concurrently
with rifampicin. Isoniazid-induced ALT elevation occurs in
>20% of subjects exposed to the drug.
The risk of developing hepatitis is age related. Approximate
case rates by age are: 0 per 1,000 for persons under 20 years
of age, 3 per 1,000 for persons in the 20–34 year age group, 12
per 1,000 for persons in the 35–49 year age group, 23 per 1,000
for persons in the 50–64-year age group, and 8 per 1,000 for persons
over 65 years of age.
Peters TS.
Do preclinical testing strategies help predict human hepatotoxic potentials?
Toxicol Pathol. 2005;33(1):146-54. Review.
